Pubished by Siemens
FOURTH QUARTER RESULTS AND PRELIMINARY FIGURES FOR FISCAL YEAR 2021
Siemens Healthineers AG today announced its results for the fourth quarter of fiscal year 2021 that ended September 30, 2021.
Fiscal Year 2021 – Outstanding performance in a challenging environment
- Record revenue of around €18 billion; comparable growth of 19.3% compared to the prior year which was challenged by the COVID-19 pandemic
- Very good comparable revenue growth of 11.8%, excluding rapid COVID-19 antigen tests; revenue contribution from rapid antigen tests of around €1.1 billion
- Considerable comparable revenue growth of 11.2% in Imaging, 8.6% in Advanced Therapies, and 42.3% in Diagnostics, excluding rapid antigen tests at 14.7%
- Excellent start of Varian within Siemens Healthineers; strong revenue contribution of €1.3 billion since the closing of the acquisition on April 15, 2021
- Adjusted EBIT margin increases by 190 bps to 17.4%
- Adjusted basic earnings per share up 26% to €2.03
- Free cash flow reaches record level of around €2.3 billion
- Proposed dividend of €0.85 per share (corresponding to a 55% pay-out ratio of net income)
Q4 Fiscal Year 2021 – Strong final quarter with peaks in order intake and revenue
- Very good revenue development also in the fourth quarter – comparable growth of 14.4% from prior-year quarter which was considerably challenged by the COVID-19 pandemic; excluding rapid antigen tests, it was 10.3%
- Equipment book-to-bill ratio at a very good 1.17
- Diagnostics revenue with excellent increase of 22.3% year-over-year; excluding the revenue contribution of around €160 million from rapid COVID-19 antigen tests, comparable revenue growth at 7.0%
- Comparable revenue growth of 11.6% in Imaging; Advanced Therapies grows by 14.5%
- Continued strong Varian development with equipment book-to-bill ratio of 1.59
- Adjusted EBIT up to €793 million compared to €631 million in the prior year – margin at 15.3%
- Adjusted basic earnings per share up 10% to €0.53 from €0.48 in the prior-year quarter
Outlook for Fiscal Year 2022
- Comparable revenue growth between 0% and 2% expected
- Excluding revenue from rapid COVID-19 antigen tests, comparable revenue growth between 5% and 7% expected
- Adjusted basic earnings per share between €2.08 and €2.20
Bernd Montag, CEO of Siemens Healthineers AG:
»The Siemens Healthineers team successfully ended the record year 2021 with a strong quarter. We demonstrated an agile and prudent response to the pandemic. As a result, we were able to gain further market shares. At the same time, we have introduced significant innovations to the market and adopted an ambitious sustainability program. Together with our colleagues from Varian, we have defined our strategic priorities for the coming years. We start the new fiscal year as an even more holistic and relevant healthcare company with a record order backlog, and we expect to continue our strong business development.«